Use of alemtuzumab as graft-versus-host disease prophylaxis in myeloablative unrelated donor transplants

7045 Background: Graft-versus-host disease(GvHD) remains a frequent, morbid, and costly complication of allogeneic stem cell transplant (alloSCT) when using unrelated donors(URD). Optimal prophylax...